Researchers investigating ways to improve type 2 diabetes treatments

June 23, 2014

A better understanding of how the transcription factor Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) works is critical to find new ways to improve medications to treat type 2 diabetes. Drugs that activate PPARgamma, called thiazolidinediones (TZDs), have long been regarded as a treatment for type 2 diabetes based on their anti-inflammatory and potent insulin-sensitizing activity. When taken orally, TZDs help decrease insulin resistance. However, most medications in that class have now been withdrawn from the market, or severely limited in their usage, given their dangerous side effects, which include weight gain, water retention and heart failure.

One promising approach to target PPARgamma to treat the issues related to is to dissect the regulatory strategies that control different subsets of PPARgamma target genes in cells. The ultimate goal would be to target the "negative" side of PPARgamma activity without impacting on the "good" ones.

A recent study led by BUSM researchers, published in Cell Reports, identifies one such strategy regulating fat tissue activity and PPARgamma in adipose cells. It is based on a group of cellular factors that bind to DNA and help PPARgamma in the regulation of a specific subset of target genes, including enzymes important for the mobilization of lipids.

"There is a great need to develop new treatments for people with type 2 ," said Valentina Perissi, PhD, assistant professor of biochemistry at BUSM and the study's corresponding author. "Targeting PPARgamma still represents a powerful approach, however we need to further improve our understanding of PPARgamma function and how its activity is regulated in in orderdevelop more effective treatments."

Explore further: Scientists find 'dual switch' regulates fat formation

More information: "GPS2/KDM4A Pioneering Activity Regulates Promoter-Specific Recruitment of PPARγ." M. Dafne Cardamone, Bogdan Tanasa, Michelle Chan, Carly T. Cederquist, Jaclyn Andricovich4, Michael G. Rosenfeld, Valentina Perissi. Cell Reports Published Online: June 19, 2014. DOI: dx.doi.org/10.1016/j.celrep.2014.05.041

Related Stories

Scientists find 'dual switch' regulates fat formation

April 8, 2011

New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.

Researchers identify key regulator of inflammatory response

April 12, 2012

(Medical Xpress) -- Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis. These findings could help lead to the development ...

Gene behind unhealthy adipose tissue identified

May 22, 2014

Researchers at Karolinska Institutet in Sweden have for the first time identified a gene driving the development of pernicious adipose tissue in humans. The findings imply, which are published in the scientific journal Cell ...

Recommended for you

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.